sef-TOL-o-zane/taz-oh-BAK-tam
Therapeutic Classification: anti-infectives
Pharmacologic Classification: cephalosporin derivatives, beta lactamase inhibitors
Absorption: IV administration results in complete bioavailability.
Distribution: Unknown.
Metabolism/Excretion: Ceftolozane: minimal metabolism; excreted almost entirely (>95%) unchanged in urine; tazobactam: 80% excreted unchanged in urine; some metabolized to an inactive M1 metabolite, which is excreted unchanged in urine.
Half-Life: Ceftolozane: 2.8 hr; tazobactam: 0.9 hr.
Complicated Intra-Abdominal Infections or Complication Urinary Tract Infections
- IV (Adults ): 1.5 g (1 g ceftolozane/0.5 g tazobactam) every 8 hr for 4–14 days for complicated intra-abdominal infection or 7 days for complicated urinary tract infection.
- IV (Children <18 yr and eGFR >50 mL/min/1.73 m2): 30 mg/kg (max dose = 1.5 g) every 8 hr for 5–14 days for complicated intra-abdominal infection or 7–14 days for complicated urinary tract infection.
Renal Impairment
- (Adults ): CCr 30–50 mL/min: 750 mg (500 mg ceftolozane/250 mg tazobactam) every 8 hr; CCr 15–29 mL/min: 375 mg (250 mg ceftolozane/125 mg tazobactam) every 8 hr; End-stage renal disease on hemodialysis: Single loading dose of 750 mg (500 mg ceftolozane/250 mg tazobactam); then 150 mg (100 mg ceftolozane/50 mg tazobactam) every 8 hr (on dialysis days administer as soon as possible after dialysis).
Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
- IV (Adults ): 3 g (2 g ceftolozane/1 g tazobactam) every 8 hr for 8–14 days.
Renal Impairment
- (Adults ): CCr 30–50 mL/min: 1.5 g (1 g ceftolozane/0.5 g tazobactam) every 8 hr; CCr 15–29 mL/min: 750 mg (500 mg ceftolozane/250 mg tazobactam) every 8 hr; End-stage renal disease on hemodialysis: Single loading dose of 2.25 g (1.5 g ceftolozane/0.75 g tazobactam); then 450 mg (300 mg ceftolozane/150 mg tazobactam) every 8 hr (on dialysis days administer as soon as possible after dialysis).